CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 34 enrolled
Drug / intervention
tamsulosin (Astellas) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02417844
NCT02417844Phase 1Completed
CompareCT.gov

Single Center, Single Dose, Open-label, Randomized, Two-way Crossover Study to Determine Bioequivalence of Two Formulations Containing Tamsulosin HCl 04.mg MR Capsules in at Least 30 Healthy Male Subjects Under Fed Conditions

Boehringer Ingelheim·interventional·Posted Apr 16, 2015·Updated Apr 17, 2020

In Brief

A Phase 1 clinical trial evaluating tamsulosin (Astellas) and Tamsulosin HCL for Prostatic Hyperplasia. Completed, enrolled 34 participants.

Detailed Summary

Two tamsulosin HClformulations will be tested in fed state

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstatic Hyperplasia
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 16, 2015
Enrollment StartApr 1, 2015
Primary CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 11.2 years ago

Interventions

tamsulosin (Astellas)drug

Tamsulosin HCLdrug